Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Our company
Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue generation.
Numinus R&D is developing psychedelic-assisted therapeutic protocols to embed in mainstream healthcare, led by medical leadership with global research and policy reform experience.
Numinus Health delivers treatments to patients through clinics and virtual services, for physical, mental, and emotional healing
https://numinus.ca/investors
Special Access for psilocybin & MDMA
Pending approval of regulatory change, Numinus intends to support patients in obtaining Special Access to psychedelic-assisted psychotherapies for a range of conditions, to be offered through our clinics in Vancouver and Montreal.
Health Canada has posted its Notice of Intent, subject to public consultation, to revise its Special Access Programme to allow legal access to psilocybin and MDMA outside of clinical trials, while the substances await formal approvals.
Numinus is undertaking two compassionate access clinical trials, which will be conducted in our Vancouver clinic. Both trials will be open to Canadian participants.
MDMA-assisted psychotherapy for PTSD, in collaboration with psychedelic research pioneer MAPS
Psilocybin-assisted psychotherapy for substance use disorders
https://numinus.ca/clinics
always always the same , always the same.
i invested 2 days ago at the high of the week and as always, always, the stock goes down.
Interesting article from the Washington Post... this is my favorite quote...
And many in the investor class see a bright future for magic mushrooms. In September, U.S. News & World Report speculated that psilocybin could beat out cannabis as a hot investment, citing a market analysis estimating the psilocybin market may grow to $100 billion.
Will psychedelic mushroom vacations come to the U. S.?
The palm-fringed beachfront and breezy cabanas at MycoMeditations are the stuff of glossy travel brochures, but the barefoot vacationers roaming the Jamaican retreat center this winter are seeking a different kind of trip entirely.
They’re here for facilitated sessions using psychedelic psilocybin mushrooms. One of a handful of established psilocybin retreat centers in the world, MycoMeditations was founded in 2015, and in the years since has seen surging interest in the reputed mental health benefits of psychedelics. Often, it’s from people surprised to find themselves seeking help from a mysterious fungus at all.
“In my life I had never done any psychedelic,” said Jessica Young, a 41-year-old executive from Atlanta, who flew to Jamaica for a MycoMeditations retreat in November 2019. “It’s pretty out of character for me.”
Like many Americans unfamiliar with crystal magic or jam band music, Young knew little about psychedelics before reading the best-selling 2018 book “How to Change Your Mind,” by journalist Michael Pollan.
In it, Pollan surveys recent research into psychedelics, which show promise for maladies from treatment-resistant depression to end-of-life distress. Such professorial passages alternate with Pollan’s eyebrow-raising personal experiences with psychedelics including psilocybin, LSD and the crystallized venom of a Sonoran Desert toad.
Young had just turned 40 when she read the book, and she was intrigued by the promise of personal growth that psilocybin seemed to offer. But despite the relative mainstreaming of psychedelics in recent years, psilocybin mushrooms are ranked alongside heroin as a Schedule 1 drug in the United States. To try them legally — an important stipulation for Young — she would have to look abroad.
“Psilocybin is not illegal here, and it’s one of the few places in the world where you can actually use these substances,” said Justin Townsend, MycoMeditations’ CEO and head facilitator. (The Netherlands, where a legal loophole allows for the sale of psilocybin sclerotia, or “truffles,” is another major destination.)
But over recent months, decriminalization efforts have opened a chink in the United States’ forbidding drug laws. In November, D.C. voters approved a ballot initiative to decriminalize the use of psilocybin mushrooms, while Oregonians approved the legal use of psilocybin in therapeutic settings. If restrictions continue to loosen, could stateside psychedelic getaways be America’s next big wellness-travel trend?
Demand is there. Each month, the inbox of researcher Robin Carhart-Harris fills with requests, sometimes pleas, to join clinical trials at the Centre for Psychedelic Research that he heads at Imperial College London.
When it comes to the healing power of psychedelics, “demand vastly exceeds supply,” Carhart-Harris said. “They’re suffering, and they’re desperate, and other treatments maybe aren’t working.” When it launched in 2019, the center became the world’s first formal site focusing exclusively on psychedelic research; later that same year, Johns Hopkins opened the Center for Psychedelic and Consciousness Research.
Promising findings about psychedelics include treatments for trauma, anorexia, treatment-resistant depression, addiction and more. Many of those who contact Carhart-Harris in hopes of joining a clinical study are suffering from these. “Often it’s really sad,” he said. “A few a day is typical, and we can’t do anything.”
Retreats step into the void between the swelling interest in psychedelic therapy and the tightly controlled trials carried out at the new research centers. And those retreats run a remarkable gamut. Some employ the language, tone and sleekly modern aesthetic of upscale clinics; others are crunchy, off-grid hippie getaways with training lineages rooted in shamanism.
Carhart-Harris’s research has convinced him that psychedelics can facilitate profound transformations, and he’s optimistic about their use beyond the lab. When compared with other drugs — or even alcohol — psilocybin is remarkably safe. It’s not addictive, and toxicity is very low.
In 2018, Carhart-Harris and a team of other researchers published survey results focused on psychedelic experiences “in the wild” — people who got their own stash of drugs and launched into orbit without supervision from a PhD. Overall, respondents did well. “That aggregate data is tending toward improvement,” Carhart-Harris said. “Any negative changes in mental health outcomes are very much the anomaly.”
In addition to offering legal alternatives to an at-home trip, retreats provide support, with the possibility of post-trip counseling to help with “integration,” a meaning-making process many believe is essential. But Carhart-Harris also sees pitfalls in the drugs’ very promise. “It’s easy to see how powerful they are,” he said. “It’s unusual to find drugs, or any intervention, that could change people as reliably. That power requires some responsibility and careful thought around harnessing it safely.”
Writer Michelle Janikian, author of the 2019 book “Your Psilocybin Mushroom Companion,” has volunteered at and participated in magic-mushroom retreats, and echoed Carhart-Harris’s caution. “Folks need to research their retreat leaders,” she said. “Do your homework first to make sure it’s a safe and integral place.”
But Janikian, like many in the world of psychedelics, welcomes the nascent push to legalize and decriminalize psilocybin in the Unites States. “I’m very excited to see how it continues to go — I think the recent passage in Oregon is going to have kin’s of a ripple effect.”
And many in the investor class see a bright future for magic mushrooms. In September, U.S. News & World Report speculated that psilocybin could beat out cannabis as a hot investment, citing a market analysis estimating the psilocybin market may grow to $100 billion.
Retreats could be part of that growth. Within days of the Oregon vote to legalize psilocybin use in therapeutic settings, Oregon-based Silo Wellness — which cultivates psychedelic mushrooms in Jamaica — announced an Oregon wellness retreat using the drug ketamine. For five socially distanced days in January, a small group will explore waterfalls, go white-water rafting, meditate and undergo three sessions of ketamine-assisted therapy led by naturopath Matthew Hicks.
Silo Wellness founder Mike Arnold described the ketamine sessions as the first legal psychedelic retreat to take place in the United States. (There’s a long-running underground of unsanctioned psychedelic retreats across the country.) Next, he’s planning psilocybin retreats in Jamaica and hopes that soon they’ll be taking place closer to home. Arnold, who would like to see the state become a psychedelic retreat destination, is staking his company on psilocybin’s potential to expand both markets and minds.
What will that mean for Americans? For Young, who traveled to Jamaica in 2019, the experience was transformative. While she worried she would find a bunch of partying bros, her 2019 retreat was anything but. Instead, she was part of an 11-person cohort that included six women, more than one grandmother, medical and mental health professionals, scientists and a construction worker.
“Everyone was there with the intention to do some serious work,” Young said. So was she: Over three psilocybin sessions, Young said she grew in ways that years of therapy hadn’t achieved. In November 2020, she returned for a second retreat. “I came out of that with this very deep knowing that this life force that’s all around us — what I would call love, essentially — is abundant, is ever present,” Young said. “I know that sounds like it comes from a pack of tarot cards. But for me, it’s profound.”
https://www.washingtonpost.com/lifestyle/travel/psychedelic-mushrooms-retreats-vacations-psilocybin/2021/01/07/fd7e998e-4f83-11eb-b96e-0e54447b23a1_story.html
LKYSF is getting equity position in Optimi Health as part of agreement! This has SO much room to run!
LKYSF SIGNS NEW CONTRACT!!
Numinus Wellness : Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products
01/06/2021 | 08:01am EST
share with twitter
share with LinkedIn
share with facebook
The agreement will focus on developing safe, effective, all-natural products for the emerging psychedelic industry
VANCOUVER, BC, Jan. 6, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp. ("Optimi"), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, to further the research and development of Canadian-grown psilocybin-producing mushrooms.
Numinus Wellness Inc. Logo (CNW Group/Numinus Wellness Inc.)
Through this first-of-its-kind agreement, Optimi will utilize and leverage Numinus Bioscience's laboratories, equipment, services and expertise, with the goal of developing products for the emerging psychedelic industry. Optimi has applied to Health Canada for a research exemption allowing it to conduct activities involving psychedelic compounds and, in advance of approval, will undertake a number of research and development projects with Numinus related to Psilocybe mushrooms, psychedelic compounds, and formulations.
"We're excited to partner with Optimi and its highly experienced and passionate team to advance psychedelic initiatives and develop safe and effective products," said Payton Nyquvest, CEO, Founder and Chairman, Numinus. "Demand for natural products that optimize mental health and performance continues to grow, and we see great potential in psilocybin-producing mushroom products to provide these benefits. We look forward to working with Optimi to advance development in this rapidly expanding marketplace."
"Numinus is an ideal partner to further our research and development of Psilocybe mushroom and associated derivatives-based products," said Mike Stier, CEO, Optimi Health Corp. "Numinus' state-of-the art laboratory, specialized equipment and second-to-none expertise in psychedelic research will be critical to developing the safe, effective, all-natural products that we believe to be the flagship products in this space."
Under the terms of the agreement, Optimi will pay an initial retainer with fees for services determined and replenished on a project-by-project basis. Each project is expected to be a stand-alone project that is defined by a Statement of Work, and while certain projects may build upon previously completed ones, there may also be several projects undertaken at the same time. Optimi will further issue to Numinus 150,000 fully paid and non-assessable common shares in the capital of Optimi (each a "Share") on January 4, 2021 and 150,000 Shares upon completing the first project that the parties enter into. All shares will be subject to resale restrictions expiring four months and one day from their date of issue.
Numinus Bioscience's laboratory provides services including cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics. The agreement with Optimi is effective January 4, 2021 and constitutes one of the first opportunities for Numinus to generate revenue from independent parties utilizing its state of the art laboratory facility, scientific expertise, and authorization to work with controlled drugs and substances.
https://www.marketscreener.com/quote/stock/NUMINUS-WELLNESS-INC-49477056/news/Numinus-Wellness-Signs-Lab-Services-Agreement-with-Optimi-Health-to-Advance-Research-and-Developme-32131230/
Maybe don’t asked insincere questions and just short the stock instead if you think its going lower. After all the only way one is truly “right” in investing is in your account balance. Not on a message board.
ridiculess - clueless - YES but who?
Now i know, thank you
(i think you would have learned from me more than I from you) but you like to learn it the hard way in loosing money.
sorry for you
Okay, you are clueless. I am putting you on ignore now.
Volume gets soaked up and price moves higher. Not sure how you think you can know the intentions of participants of the offering but the offering and it’s terms are not a big deal imo. If you’re not comfortable with it maybe it’s not the stock for you. there are tons of stocks out there to choose from. Gl
thanks and much appreciation for you2. and . . . i dont wanna annoy you!
1. i know the market in general will explode
2. i know we are well financed. (the money "arrived" at KKYSF)
3. i know sp tend to go down to offering price and then, with good news and perspective sp rises.
BUT
the entities who gave the money aren `t long termers. They want their money back earlier. They sell after every sp increase: over .35 - over .60 - over .90 and shorters know that!
No. The offering will only affect the share price in the short term, generally until the offering closes. Then the share price will start going back up. To sell and wait to buy again in 2022 would be the opposite of a good strategy. The proper strategy would be to buy as many shares as you can now, when the price is temporarily low, and hold those shares for years. We all know the psychedelic sector is going to explode over the next 3-5 years. If you buy in 2022, it is too late.
I think the important thing is they have plenty cash now and the opportunity here imo is much more that this going to $1. LKYSF comments below from deal closing PR seems to indicate we can expect much more news in 2021.
In addition to the bought deal public offering, over the past 12 weeks, Numinus has received approximately $8.9 million in gross proceeds from the exercise of warrants and stock options.
"This over-subscribed financing, along with the exercised warrants and options, not only strengthens our cash position, but clearly demonstrates confidence in our business model, our progress, and our growth prospects," said Payton Nyquvest, Founder, CEO, and Chair, Numinus. "We are closing off 2020 in a strong position with the financing topping off our recent exclusive Psilocybe harvest and extraction, our planned compassionate access trial of psilocybin, our partnership with MAPS for an MDMA compassionate access trial, our national expansion with the acquisition of Mindspace, and our successful lobbying of Health Canada resulting in its notice of intent to amend the Special Access Programme to include accessibility to psilocybin and MDMA. We are ready for a fast-paced year ahead, and I would like to use this opportunity to sincerely thank our supporters and to wish you all a healthy, safe and happy New Year."
Thanks for the info and
Hello
i am new to the shroom/psy-market and looking for comp. which haven`t had too much gains already. so i came across LKYSF.
lets get this in short: offering 25,367,850 Units, purchase price of $0.68 and for 2 Common Shares one warrant, exercisable until December 29, 2022 for $0.90
(+ cash commissions, Over-Allotment Options, fees. )
ADDITIONALLY the first finance with the right to buy at .35 cents expiring Sept. 10th 2022.
clearly nothing special (worse or good) just commen in this stage.
O.K. is the last offering 0,68 a normal discount to sp! warrant ex-price slightly over current valuation. Worst are the .35cent. So, everything is primed for dilution here.
( .35 .68. max sp possible .80 .90 then selling pressure, in 2022 sp at 1.20- max 1.50 for selling the last offer warrants)
I think everyone who bought in at lower prices should sell and we all wait until mid 2022? or is there anything i missed here. I am willing to learn.
I wish you all a healthy New Ear (listening is better than talking)
Psilocybin Could be Key to Helping Millions of People with Eating Disorders
https://t.co/70HAPXZkhH?amp=1
Numinus tweet in last couple minutes... HUGE for MMEDF and LKYSF!
If the revision to Health Canada’s Special Access Program is made, psychedelic-assisted psychotherapy would be made more accessible to those who need it. This shift, among many other recent developments in the industry, have caught @Forbes eye. Read the full article here:
— Numinus (@NuminusHealth) December 30, 2020
LKYSF fills the coffers with cash....
Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
VANCOUVER, BC, Dec. 29, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has closed its previously announced bought deal public offering (the "Offering") of units (the "Units") through Canaccord Genuity Corp. and Eight Capital (the "Underwriters") pursuant to a short form prospectus dated December 21, 2020.
Pursuant to the Offering, the Company issued 25,367,850 Units, on an underwritten basis, at the purchase price of $0.68 per Unit (the "Offering Price"), for aggregate gross proceeds to the Company of $17,250,138, which includes the exercise, in full, by the Underwriters of the over-allotment option (the "Over-Allotment Option") granted by the Company to purchase an additional 3,308,850 Units at the Offering Price.
Each Unit consists of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant is exercisable to acquire one Common Share until December 29, 2022 at an exercise price of $0.90 per Common Share.
In consideration for their services, the Company paid to the Underwriters a cash commission equal to 6% of the aggregate gross proceeds of the Offering in the amount of $1,035,008.28, including gross process raised on exercise of the Over-Allotment Option, and issued to the Underwriters 1,522,071 compensation warrants (the "Compensation Warrants"). Each Compensation Warrant may be exercised to acquire one Common Share (each, a "Compensation Share") at an exercise price of $0.68 per Compensation Share until December 29, 2022.
In addition, the Company paid a corporate finance fee (the "Corporate Finance Fee") in the amount of $250,000 with 50% of the Corporate Finance Fee paid in cash and 50% of the Corporate Finance Fee paid in Common Shares (the "Corporate Finance Fee Shares") at a deemed price of $0.68 per Corporate Finance Fee Share for a total of 183,824 Corporate Finance Fee Shares.
The Company intends to use the net proceeds of the Offering for clinic upgrades to prepare for clinical trials, laboratory upgrades, clinic acquisitions, research and development of medical protocols, and general working capital.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.
In addition to the bought deal public offering, over the past 12 weeks, Numinus has received approximately $8.9 million in gross proceeds from the exercise of warrants and stock options.
"This over-subscribed financing, along with the exercised warrants and options, not only strengthens our cash position, but clearly demonstrates confidence in our business model, our progress, and our growth prospects," said Payton Nyquvest, Founder, CEO, and Chair, Numinus. "We are closing off 2020 in a strong position with the financing topping off our recent exclusive Psilocybe harvest and extraction, our planned compassionate access trial of psilocybin, our partnership with MAPS for an MDMA compassionate access trial, our national expansion with the acquisition of Mindspace, and our successful lobbying of Health Canada resulting in its notice of intent to amend the Special Access Programme to include accessibility to psilocybin and MDMA. We are ready for a fast-paced year ahead, and I would like to use this opportunity to sincerely thank our supporters and to wish you all a healthy, safe and happy New Year."
https://www.newswire.ca/news-releases/numinus-announces-closing-of-17-million-bought-deal-offering-including-full-exercise-of-over-allotment-option-849922746.html
Seeking Alpha article out this morning about LKYSF.....
Summary
The Canadian government continues to make moves in favour of psychedelics.
Diagnosis rates of depression and anxiety are higher than ever, pathing a way for psychedelics to become a legit alternative treatment option.
Numinus will benefit from changing consumer views about psychedelics.
The company has a first-mover advantage because of its ketamine-enabled clinics and strong research team.
https://seekingalpha.com/article/4396322-numinus-bet-on-changing-landscape-of-therapeutic-drugs
What is going on here???? Why no PR? What kind of CEO would let their stock tank with good news (MAPS story) and NO PR???
Anyone here know what % the insiders own? I cant seem to find it. Thanks in advance
Call Numinus and tell them to do their job and issue PR. Stock
Should be screaming on MAPS NEWS.
833-686-4687
MAPS Rick Doblin posted tweet about phase 3. Why no PR by Numinus? Should be screaming
If they would just post news about partner.
https://mobile.twitter.com/RickDoblin
Traded them in tho for PHRM.CA and LOBE.CA ?
No matter tho since those're also doing just fine.....but here we have Numinus - The Worlds' Global Leader !
Absolutely, it has, and my apologies for not being more specific. This is penny land. And many in penny land fail to appreciate quality stocks that will actually sustain gains and go to levels 99.9% don’t ever come close to attaining. For those who got in low and already saw 3-5x gains, awesome. Congrats to them for having gotten in early. Many followed your lead and bought higher. Someone said this is unchartered waters. He/she is absolutely correct, especially in this space. For most, this range is risky. I believe there are many who will get in and out. But for those with wider vision, especially for those who got in early, this is going to help towards their retirement plans. GLTA
Ummm, it already has run up a lot.
lol...its already run from 20c so I have no idea what you're talking about.
One day, this will run. And when folks look at this message board when it inevitably becomes more active, they’ll see they could have had this at $1-$1.50. 3-5x lower in price. I believe the new year will bring major new investment to the space, particularly this gem.
The biggest shroomer explodes into close
going higher
Only way to get exposure to MAPS. MAPS will have phase 3 data out next year. Cure for ptsd and export license for numinous and uplist to NASDAQ.
They will dilute and then reverse split. Watch and learn!
LOLOL
People definitely need to tread with caution with your always flawed analysis!
ROFLMAO
They are rotating them, trade with caution, they don't have fundamentals and they never will. Very early in the the space, so they are all Option and warrant runs. This one had a nice run. Lots of low life weed stocks making the switch in Canada. LOBE.CA just did the switch and company symbol change.
I traded this in for PHRM.CA and LOBE.CA
been here for a long time.
The right to buy at .35 cents expiring Sept. 10th 2022
https://numinus.ca/investors/news-release/numinus-announces-listing-of-warrants
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=ca%3Anumi&x=0&y=0&time=100&startdate=1%2F4%2F2020&enddate=11%2F27%2F2020&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=ca%3Anumi.wt&x=41&y=15&time=100&startdate=1%2F4%2F2020&enddate=11%2F27%2F2020&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9
Yeowsa.....
Global risk-ON eh ?.....In virtually EVERYTHING
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159769961
Weill be interesting see how things transpire week (probably continue) - UP
Nice day and looking forward to the ride up ahead!
NUMI.V get ready to rumble...shrooms about to go nutzo!!
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
V.NUMI | 4 hours ago
https://stockhouse.com/news/press-releases/2020/11/18/numinus-announces-compassionate-access-trial-of-psilocybin-assisted
VANCOUVER, BC , Nov. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will enable the company to implement, test, and refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders and will be conducted in collaboration with Syreon Corporation , a global contract research organization with expertise in conducting clinical trials across a broad range of chronic and complex diseases. The study will involve an initial 30 participants who will take part in a motivational enhancement psychedelic psychotherapy intervention with psilocybin.
Psilocybin: These are Some Top Companies That Could Benefit from Legalization
CMPS, V.NUMI, C.FTRP | 4 hours ago
https://stockhouse.com/news/press-releases/2020/11/06/psilocybin-these-are-some-top-companies-that-could-benefit-from-legalization
The psychedelics story has just begun to gain momentum. We’re already seeing a good deal of clinical studies on psilocybin for example, for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression and anxiety. We’re also just beginning to see broader support in the U.S. In fact, over the last few months, Denver, Oakland, and Santa Cruz have legalized the use of psilocybin. Earlier this week, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, "An estimated 1 in every 5 adults in Oregon is coping with a mental health condition," 20 doctors and other health care workers wrote in the voters’ pamphlet. With excitement gaining momentum, some of the top companies to watch include CYBIN Inc., Mind Medicine Inc. (OTC:MMEDF), COMPASS Pathways (NASDAQ:CMPS), Numinus Wellness Inc. (TSXV:NUMI), and Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF).
Numinus Wellness Inc. (TSXV:NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, has harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer's Licence. This news coincides with other recent developments by Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory, which is focused on handling various psychedelic substances and developing analytical methods and formulations for the evolving psychedelics space. "The first harvest of legally grown Psilocybe mushrooms is a significant milestone for the whole industry" said Michael Tan, Chief Operating Officer. "Now, we can progress with research and development of standardized cultivation, extraction, and testing methods and exploring product formulations to support safe, evidence-based, accessible psychedelic-assisted psychotherapy, as well as build a sequenced spore library."
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
130
|
Created
|
05/20/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |